NCT02194738 2026-03-18
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
Clinical Trials
12 trialsNCT00883480 2022-06-13
SLAT
Spanish Lung Cancer Group
Phase NA Completed
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
NCT00125372 2019-01-08
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT02450591 2018-05-21
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02013089 2016-08-30
GITIC
Sun Yat-sen University
Phase NA Unknown
NCT00144976 2015-03-27
Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma
Institut Claudius Regaud
Phase NA Completed
NCT00085280 2014-03-31
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase NA Completed
NCT01776684 2013-01-28
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Samsung Medical Center
Phase NA Unknown
NCT00903292 2009-05-18
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
National Cheng-Kung University Hospital
Phase NA Unknown